No abstract

Early rapid platelet inhibition with abciximab before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is suggested as beneficial. In previous studies on early abciximab administration clopidogrel was administered in cathlab in low loading dose. We investigated the role of early abciximab administration on top of early clopidogrel 600 mg loading dose in patients with STEMI treated with PPCI. A total of 73 non-shock STEMI < 6 h patients admitted to remote hospitals with anticipated delay to PPCI < 90 min were randomly assigned to three study groups--24 pts received abciximab before transfer to cathlab (early = group EA), 27 in cathlab during PPCI (late = group LA) and in 22 abciximab administration was left to operator's discretion during PPCI (selective = SA; given in 22.7% of patients). All patients received clopidogrel (600 mg), aspirin and heparin (70 U/kg) before transfer to cathlab. Angiography revealed more frequent infarct-related artery patency (TIMI 2 + 3: EA vs LA vs SA: 45.8 vs 18.5 vs 13.6%, P = 0.024), better myocardial tissue perfusion (MBG 2 + 3: EA vs LA vs SA: 45.8 vs 14.8 vs 13.6%, P = 0.02) in EA group in baseline angiography. There was no difference in these angiographic parameters and ECG ST-segment resolution after PPCI. In multivariate analysis early abciximab administration was an independent predictor of infarct-related artery patency in baseline angiography (OR 6.5; 95% CI 1.83-23.1; P = 0.004). Early abciximab administration before transfer for PPCI in patients with STEMI pretreated with 600 mg of clopidogrel results in more frequent infarct-related artery patency and better myocardial tissue perfusion before PPCI.

No abstract

ImportanceIn patients with multivessel coronary artery disease (CAD) presenting with ST-segment elevation myocardial infarction (STEMI), complete revascularization reduces major cardiovascular events compared with culprit lesion–only percutaneous coronary intervention (PCI). Whether complete revascularization also improves angina-related health status is unknown.ObjectiveTo determine whether complete revascularization improves angina status in patients with STEMI and multivessel CAD.Design, Setting, and ParticipantsThis secondary analysis of a randomized, multinational, open label trial of patient-reported outcomes took place in 140 primary PCI centers in 31 countries. Patients presenting with STEMI and multivessel CAD were randomized between February 1, 2013, and March 6, 2017. Analysis took place between July 2021 and December 2021.InterventionsFollowing PCI of the culprit lesion, patients with STEMI and multivessel CAD were randomized to receive either complete revascularization with additional PCI of angiographically significant nonculprit lesions or to no further revascularization.Main Outcomes and MeasuresSeattle Angina Questionnaire Angina Frequency (SAQ-AF) score (range, 0 [daily angina] to 100 [no angina]) and the proportion of angina-free individuals by study end.ResultsOf 4041 patients, 2016 were randomized to complete revascularization and 2025 to culprit lesion–only PCI. The mean (SD) age of patients was 62 (10.7) years, and 3225 (80%) were male. The mean (SD) SAQ-AF score increased from 87.1 (17.8) points at baseline to 97.1 (9.7) points at a median follow-up of 3 years in the complete revascularization group (score change, 9.9 [95% CI, 9.0-10.8]; P &lt; .001) compared with an increase of 87.2 (18.4) to 96.3 (10.9) points (score change, 8.9 [95% CI, 8.0-9.8]; P &lt; .001) in the culprit lesion–only group (between-group difference, 0.97 points [95% CI, 0.27-1.67]; P = .006). Overall, 1457 patients (87.5%) were free of angina (SAQ-AF score, 100) in the complete revascularization group compared with 1376 patients (84.3%) in the culprit lesion–only group (absolute difference, 3.2% [95% CI, 0.7%-5.7%]; P = .01). This benefit was observed mainly in patients with nonculprit lesion stenosis severity of 80% or more (absolute difference, 4.7%; interaction P = .02).Conclusions and RelevanceIn patients with STEMI and multivessel CAD, complete revascularization resulted in a slightly greater proportion of patients being angina-free compared with a culprit lesion–only strategy. This modest incremental improvement in health status is in addition to the established benefit of complete revascularization in reducing cardiovascular events.

A b s t r a c tBackground: In patients with acute ST segment elevation myocardial infarction (STEMI), primary percutaneous coronary intervention (PCI) is the preferred reperfusion method over fibrinolysis, if it is performed in a timely fashion by an experienced team in a centre with on-site primary PCI service. Treatment delay due to patient transfer to the cardiac catheterisation laboratory is an important limitation of mechanical reperfusion in STEMI patients. Aim:To analyse treatment outcomes in STEMI patients hospitalised in a regional hospital in Tarnow before and after introduction of a 24/7 primary PCI service.Methods: Enrolment into the registry continued for 12 months before introduction of a 24/7 primary PCI service (Period I: 19.04.2004(Period I: 19.04. -19.04.2005) and 15 months after introduction of a 24/7 primary PCI service (Period II: 8.08.2005-19.10.2006). Overall, 226 STEMI patients were analysed, including 115 patients in Period I and 111 patients in Period II. STEMI patients in Period I received conservative treatment (n = 59), pharmacoinvasive treatment (a half dose of alteplase, a full dose of abciximab, and transfer to a 24/7 primary PCI reference centre: n = 32) or fibrinolysis with streptokinase (n = 24), while all patients in Period II underwent primary PCI on the first day of hospitalisation. Occurrence of cardiovascular deaths, non-fatal recurrent infarctions, and revascularisation with PCI or coronary artery bypass grafting was evaluated in the two groups during 1-year follow-up. Results:Reperfusion therapy was used in 48.7% of STEMI patients in Period I (pharmacoinvasive treatment in 27.8% and fibrinolysis in 20.9%), and all patients in Period II underwent primary PCI. In-hospital mortality among STEMI patients in Period I was significantly higher than in Period II (23.5% vs. 5.4%, p < 0.001), and it was 23.7% in patients managed conservatively. The hazard ratio for Period II compared to Period I was 0.14 (95% CI 0.03-0.62, p = 0.009). A benefit of invasive treatment was seen during 1 year of follow-up (mortality 26.1% in Period I vs. 9.0% in Period II, p = 0.001). Invasive treatment was also associated with a shorter hospital stay. Conclusions:Introduction of a 24/7 primary PCI regional service (STEMI network) led to improved accessibility of invasive diagnosis and treatment and increased reperfusion treatment rates, resulting in reduced in-hospital and 1-year mortality among STEMI patients.